Full Press Release Details
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC and Option Exercise with Biocytogen.
IDYA
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC and Option Exercise with Biocytogen
Key Takeaway: IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC and Option Exercise with Biocytogen
Price reaction · baseline $31.28 (2024-11-08 close) · 2 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma